Featured Story

Pfizer turns aside yet another case alleging Zoloft caused birth defects

In what has turned into a legal trifecta for Pfizer, it has won the dismissal of a lawsuit that claimed the use of the antidepressant Zoloft during pregnancy caused birth defects in a child. The decision comes after Pfizer has won two jury verdicts in recent months over the same claims.

Backlash rages on over Purdue's pediatric OxyContin approval

Back in August, the FDA approved Purdue's powerful painkiller, OxyContin, for children ages 11 to 16. But nearly two months later, the public backlash hasn't died down.

Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects

Healthcare informatics company Advera Health Analytics delved into FDA postmarketing safety reports and compiled data on Alzheimer's drugs. The firm found that Novartis' Exelon patch, Allergan's Namenda and Eisai's Aricept showed more reports of serious side effects than other drugs, with safety issues ranging from convulsions and gastrointestinal hemorrhage to respiratory failure and sudden death.

Sun kills lawsuit Ranbaxy filed against FDA for pulling its Nexium generic

When the FDA last year yanked away its initial approval of Ranbaxy's generics of two blockbusters including the heartburn med Nexium, the Indian drugmaker fired back with a lawsuit against the FDA. But Ranbaxy is now owned by Sun Pharmaceutical, which sees no upside to fighting with the agency, and so it has dropped the litigation.

Credit Suisse analyst lifts Lilly rating on Jardiance promise

Credit Suisse analyst Vamil Divan is optimistic about sales of Eli Lilly and Boehringer Ingelheim's Jardiance. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77.


From Our Sister Sites


Medtronic announced the first implants of its deep brain stimulation system in conjunction with its bioabsorbable antibacterial envelope to prevent surgical site infections. The milestone occurred at the Barrow Neurological Institute in Phoenix. Medtronic also said it plans to soon make the technology available for use with its neurostimulators for chronic pain and bladder/bowel control disorders.


Onkos Surgical has secured a Series A financing and partnered with MicroPort Orthopedics. The financial details were undisclosed in the company's announcement, but an SEC filing reveals that Onkos recently secured the first $6.1 million of a financing that's expected to total $15.3 million.